Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.48 |
| ▸ | WDR5 | P61964 | 7/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560655 | 0.86 | ADRA2A (0.55) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL561022 | 0.86 | HTR1D (0.55) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL560664 | 0.85 | LMNA (0.56) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL561403 | 0.83 | LMNA (0.62) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL20017860 | 0.83 | SMN1; SMN2 (0.50) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL8133645 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL8148008 | 0.83 | LMNA (0.52) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL560777 | 0.80 | LMNA (0.56) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| Iodide SCHEMBL16227866 | 0.78 | LMNA (0.59) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL8133648 | 0.78 | ADRA2A (0.52) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2009152053-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATES | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | HTR1D 222/4885SMN1; SMN2 1109/4885NLRP3 3311/4885 |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | HTR1D 222/4885SMN1; SMN2 1109/4885NLRP3 3311/4885 |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.